ProKidney Corp.
PROK
Rank in Stocks
#13486
ProKidney Corp. is a biotechnology firm currently in the clinical trial phase,... ProKidney Corp. is a biotechnology firm currently in the clinical trial phase, specializing in the development of innovative cell-based treatments. Their flagship product is Renal Autologous Cell Therapy (RAC-T), a unique cellular admixture derived from a patient's own cells. RAC-T is undergoing significant clinical evaluation; it is concurrently in Phase III and Phase II trials for individuals with moderate to severe diabetic kidney disease. Furthermore, the company is conducting a Phase I clinical trial to assess RAC-T's potential for patients born with congenital anomalies affecting the kidneys and urinary tract. The company was established in 2015 and operates from its headquarters in Winston-Salem, North Carolina.
Share Price
$1.15
Last synced: 2026-11-09
Market Cap
$386.69M
Change (1 day)
0.88%
Change (1 year)
-58.93%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade ProKidney Corp. (PROK)
Category
Healthcare
Operating Margin for ProKidney Corp. (PROK)
Operating Margin as of November 2026 TTM: -21,664.55%
According to ProKidney Corp.'s latest financial reports, its current operating margin (TTM) is -21,664.55%. At the end of 2025 the company had an operating margin of -18,477.83%.
Operating Margin history for ProKidney Corp. from 2019 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -21,664.55% | 17.25% |
| 2025 | -18,477.83% | -92.35% |
| 2024 | -241,678.95% | 0.00% |
| 2023 | 0.00% | 0.00% |
| 2022 | 0.00% | 0.00% |
| 2021 | 0.00% | 0.00% |
| 2020 | 0.00% | 0.00% |
| 2019 | 0.00% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -100.00% |
US
|
|
| -149.01% | -99.99% |
US
|
|
| 25.57% | -100.00% |
AU
|
|
| 31.23% | -100.00% |
BE
|
|
| 29.35% | -100.00% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about ProKidney Corp.'s operating margin
What is ProKidney Corp.'s operating margin?
ProKidney Corp.'s operating margin is -21,664.55%, as of Nov 2026.
What was ProKidney Corp.'s operating margin in 2025?
In 2025, ProKidney Corp.'s operating margin was -18,477.83%, compared with -241,678.95% in 2024.
How has ProKidney Corp.'s operating margin changed since 2020?
From 2020 to 2025, ProKidney Corp.'s operating margin was highest in 2023 (0.00%) and lowest in 2024 (-241,678.95%).
How does ProKidney Corp.'s operating margin compare with similar companies?
ProKidney Corp.'s operating margin (-21,664.55%) is lower than that of all 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.